| Code | CSB-MP004971HU1(F2) |
| Abbreviation | Recombinant Human CD96 protein, partial (Active) |
| MSDS | |
| Size | $9.9 |
| Promotion | |
| Order now | |
| Image | |
| Have Questions? | Leave a Message or Start an on-line Chat |
CD96 functions as an emerging immune checkpoint receptor that competes with TIGIT for binding to shared ligands, making it a compelling target in immuno-oncology and T-cell regulation studies. This recombinant human CD96 construct covers the extracellular region (aa 22–503 of Isoform 2), encompassing the ligand-binding immunoglobulin-like domains, and is expressed in mammalian cells to preserve native glycosylation and conformational integrity critical for receptor-ligand interaction assays. Functional ELISA validation confirms robust binding activity, with immobilized CD96 at 2 μg/mL engaging anti-CD96 antibody at an EC50 of 95.78–127.1 ng/mL, supporting use as a positive control in binding assays, competitive blocking antibody screening, and therapeutic antibody epitope mapping. The C-terminal 10×His tag facilitates oriented immobilization for SPR or BLI affinity characterization, while purity exceeding 95% and endotoxin levels below 1.0 EU/μg satisfy the criteria typically required for sensitive immune checkpoint research and small-molecule inhibitor screening campaigns.
There are currently no reviews for this product.